Explore how thalidomide derivatives enhance T-cell responses and combat exhaustion in multiple myeloma therapies for improved patient outcomes.
David S. Siegel
Advertisement
Articles by David S. Siegel
David Samuel Dicapua Siegel, MD, shared his perspectives on promising areas of research that could advance the care of patients with myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5